SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Walther Jallow L)
 

Search: WFRF:(Walther Jallow L) > Immunization with r...

  • Nilsson, CKarolinska Institutet (author)

Immunization with recombinant modified vaccinia virus Ankara can modify mucosal simian immunodeficiency virus infection and delay disease progression in macaques

  • Article/chapterEnglish2002

Publisher, publication year, extent ...

  • Microbiology Society,2002

Numbers

  • LIBRIS-ID:oai:prod.swepub.kib.ki.se:1954180
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:1954180URI
  • https://doi.org/10.1099/0022-1317-83-4-807DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • In the present study, the immunogenicity and protective efficacy of a recombinant vaccinia virus-based simian immunodeficiency virus (SIV) vaccine, given alone or in combination with a protein boost, were investigated. Cynomolgus macaques were immunized intramuscularly with modified vaccinia virus Ankara (MVA) expressing the SIVsmenvandgag–polgenes (MVA–SIVsm) at 0 and 3 months (n=4), at 0, 3 and 8 months (n=4) or at 0 and 3 months followed by purified native SIVsm gp148 and recombinant SIVmac p27 in immunostimulatory complexes at 8 months (n=4). One month after the last immunization, the vaccinees, together with four naive control monkeys and four monkeys immunized with wild-type MVA, were challenged intrarectally with 10 MID50SIVsm. At the time of challenge, antibody titres to SIV Env and lymphocyte proliferation responses to whole viral antigen were highest in vaccinees receiving MVA–SIVsm in combination with protein immunizations. Following rectal challenge, one of these vaccinees was completely protected. A prolonged survival time was observed in two of four monkeys in each of the groups immunized with MVA–SIVsm, in two monkeys given MVA–SIVsm followed by protein and in three of four monkeys given wild-type MVA, compared with naive controls. In conclusion, one monkey given the combined vaccine was protected completely against SIVsm infection. Furthermore, immunization with MVA–SIVsm, as well as wild-type MVA alone, seemed to delay disease progression after mucosal SIV infection in a proportion of the monkeys.

Added entries (persons, corporate bodies, meetings, titles ...)

  • Sutter, G (author)
  • Walther-Jallow, L (author)
  • ten Haaft, P (author)
  • Akerblom, L (author)
  • Heeney, J (author)
  • Erfle, V (author)
  • Bottiger, P (author)
  • Biberfeld, GKarolinska Institutet (author)
  • Thorstensson, R (author)
  • Karolinska Institutet (creator_code:org_t)

Related titles

  • In:The Journal of general virology: Microbiology Society83:Pt 4, s. 807-8180022-13171465-2099

Internet link

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view